cardionovum

We, at Cardionovum have one common mission. Maintaining our technology leadership and realising innovative medical device concepts. For the best patient treatment, today as well as in the future. Cardionovum feels competent for further developments in leading edge technologies. Our clinically proven products set the benchmark for further medical therapy solutions. Cardionovum has a full R & D portfolio and promises more exceptional medical devices to be launched into the medical market to keep up with and set therapeutical trends in cardiovascular medicine. In 2007 Dr. Michael Orlowski introduced the first CE mark approved Drug-Eluting Balloon Dilatation Catheter to the market. With the first DCB market introduction the founder of Cardionovum contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively. The treatment of coronary stent-associated patient problems, like in-stent restenosis (ISR), and the treatment of peripheral artery lesions by a DCB have become the preferred treatment standard. Cardionovum consists of R & D, Sales and Marketing staff, with the longest and most profound experience, in developing of clinically advanced DCB and DES cardiovascular devices.